On January 7, 2010 Astrazeneca reported a Protein Kinase B inhibitor to be taken into clinical development, following a successful collaboration with the biotechnology company Astex Therapeutics (Press release, Cancer Research Technology, JAN 7, 2010, View Source [SID1234523341]). The PKB programme, from which the clinical candidate was selected, stemmed from collaborative research originally carried out by The Institute of Cancer Research, CRT and Astex. Click here to find out more about the deal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!